A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
BeOne Medicines
BeOne Medicines
Merck Sharp & Dohme LLC
Essen Biotech
Werewolf Therapeutics, Inc.
Australian & New Zealand Children's Haematology/Oncology Group
M.D. Anderson Cancer Center
UNC Lineberger Comprehensive Cancer Center
Recursion Pharmaceuticals Inc.
University of California, San Diego
BeiGene
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Cancer Research UK
Novartis
Intensity Therapeutics, Inc.
Genmab
Cyteir Therapeutics, Inc.
Takara Bio Inc.
Takeda
Shenzhen University General Hospital
Astex Pharmaceuticals, Inc.
Altor BioScience
AO GENERIUM
CytomX Therapeutics
Sumitomo Pharma America, Inc.
University of Nebraska
AbbVie
Asana BioSciences
National University Hospital, Singapore
Bristol-Myers Squibb
University of Birmingham
Molecular Templates, Inc.
Takeda
Swiss Cancer Institute
Beijing Immunochina Medical Science & Technology Co., Ltd.
Taiwan Liposome Company
Sunesis Pharmaceuticals
University of California, San Diego
Rigshospitalet, Denmark
Acibadem University
AHS Cancer Control Alberta
Amgen Research (Munich) GmbH
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Jichi Medical University
Philogen S.p.A.
Genta Incorporated
Amgen